Immuneel Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 111

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $10.5M

  • Investors
  • 19

Immuneel General Information

Description

Developer of cell and gene therapies designed to treat cancer. The company develops immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies, that use genetically modified human immune cells to target cancer cells, enabling cancer patients to access cell-based treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 29/P2, 8th Floor Narayana Health City
  • Hosur Road Bommasandra Industrial Area
  • Bengaluru, Karnataka 560099
  • India
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 29/P2, 8th Floor Narayana Health City
  • Hosur Road Bommasandra Industrial Area
  • Bengaluru, Karnataka 560099
  • India

Immuneel Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immuneel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 08-Jun-2026 $10.5M Completed Clinical Trials - General
3. Later Stage VC (Series A) 09-Jul-2024 Completed Clinical Trials - General
2. Early Stage VC (Series A) 11-Apr-2022 $14.2M $26.1M Completed Clinical Trials - General
1. Early Stage VC 10-Aug-2020 $11.8M $11.8M Completed Clinical Trials - General
To view Immuneel’s complete valuation and funding history, request access »

Immuneel Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A Preference
Ordinary
Series A Preference
Ordinary 10 $0.119762 $1268.76 $1268.76 1x $1268.76 0.02%
Ordinary 17,978 $0.119762 $592.82 $592.82 1x $592.82 38.77%
To view Immuneel’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Immuneel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell and gene therapies designed to treat cancer. The company develops immunotherapies, including chimeric
Drug Discovery
Bengaluru, India
111 As of 2026

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immuneel Competitors (1)

One of Immuneel’s competitors is Bugworks Research, a Private Equity-Backed company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bugworks Research Private Equity-Backed Wilmington, DE
You’re viewing 1 of 1 competitors. Get the full list »

Immuneel Patents

Immuneel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026042055-A1 Dual targeting cancer cell therapy for cd19 and cd20 Pending 23-Aug-2024
AU-2025239922-A1 A method for preparing chimeric antigen receptor (car) expressing cells Pending 18-Mar-2024
WO-2025196582-A1 A method for preparing chimeric antigen receptor (car) expressing cells Pending 18-Mar-2024
WO-2024047558-A2 Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e Inactive 31-Aug-2022
WO-2024047558-A3 Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e Inactive 31-Aug-2022 C07K16/283
To view Immuneel’s complete patent history, request access »

Immuneel Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immuneel Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Rainmatter Capital Corporate Venture Capital Minority
Singularity AMC Growth/Expansion Minority
Kotak Private Equity Group PE/Buyout Minority
taiba rare Corporation Minority
You’re viewing 5 of 19 investors. Get the full list »

Immuneel FAQs

  • When was Immuneel founded?

    Immuneel was founded in 2018.

  • Where is Immuneel headquartered?

    Immuneel is headquartered in Bengaluru, India.

  • What is the size of Immuneel?

    Immuneel has 111 total employees.

  • What industry is Immuneel in?

    Immuneel’s primary industry is Drug Discovery.

  • Is Immuneel a private or public company?

    Immuneel is a Private company.

  • What is Immuneel’s current revenue?

    The current revenue for Immuneel is .

  • How much funding has Immuneel raised over time?

    Immuneel has raised $48.5M.

  • Who are Immuneel’s investors?

    , Rainmatter Capital, Singularity AMC, Kotak Private Equity Group, and taiba rare are 5 of 19 investors who have invested in Immuneel.

  • Who are Immuneel’s competitors?

    Bugworks Research is a competitor of Immuneel.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process